Introduction
The PI3K/AKT/mTORC1 signalling hub plays an essential role in malignant transformation [1] [2] [3] [4] [5] and is dysregulated in many cancers with multiple components of this pathway being shown to act as oncogenes or tumour suppressors [3, [6] [7] [8] . Most studies examining the mechanism(s) by which this signalling hub contributes to malignancy have focused on the processes of pro-survival, cell cycle progression, angiogenesis and metabolic rate.
However, it is becoming increasingly apparent that the downstream actions of this pathway to regulate ribosome biogenesis and translation are essential for its oncogenic effects [9] [10] [11] . The oncogene MYC is dysregulated in 15 [12] [13] [14] [15] . Indeed PI3K/AKT/mTORC1 and MYC signalling can cooperate, converging at a number of steps to establish master control of ribosome biogenesis, and thus protein synthesis [4, 5, 11] . The availability of sufficient functional ribosomes is a fundamental rate-limiting step for growth and proliferation in mammalian cells [16, 17] and diseases, such as cancer, that are associated with uncontrolled growth and proliferation are frequently characterized by increased ribosome synthesis [10] . Importantly for this study, increased ribosome synthesis and subsequent modulation of the efficiency of translation of key cell proliferation, growth, and survival proteins is an essential mechanism by which MYC promotes tumourigenesis [10, [18] [19] [20] [21] [22] .
We recently demonstrated that RNA polymerase I (Pol I) transcription can be selectively targeted with the small molecule CX-5461 to treat Myc-driven Bcell lymphoma [22] . This model of spontaneous B-cell lymphoma is a prototypical example of tumour driven by uncontrolled cell growth as evidenced by the increased rates of rRNA and protein synthesis and larger size of B-cells from equivalent stages of development [22, 23] . Given the key role of AKT in MYC dependent rDNA transcription and ribosome biogenesis [11] we hypothesized that specific inhibition of AKT using the allosteric inhibitor MK-2206, currently in Phase I/II clinical trials [24] , would antagonise MYC driven rRNA synthesis in the Eμ-MYC B-cell lymphoma model and delay lymphoma progression. MK-2206 (8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl- [1, 2, 4] triazolo [3,4-f] [1, 6] naphthyridin-3(2H)-one) is a highly specific inhibitor of AKT, with low nanomolar IC 50 values for all three isoforms of AKT (AKT1 -8nM; AKT2 -12nM; AKT3 -65nM) and 100-fold selectivity for AKT over a large panel of other protein kinases [25] . By specifically targeting the pleckstrin homology domain of AKT isoforms, MK-2206 prevents recruitment of the kinase to the plasma membrane and subsequent activating phosphorylation events at threonine 308 and serine 473 residues [25] . MK-2206 at doses between 120mg/Kg and 480mg/Kg has demonstrated therapeutic properties in pre-clinical cancer models in vivo and robustly inhibited AKT activity and tumour cell growth in ovarian, lung, breast and
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© 2013 The Authors Journal compilation © 2013 FEBS neuroblastoma cancer xenograft models [25] [26] [27] [28] . In this study, MK-2206 rapidly and potently antagonised rDNA transcription, restored spleen weight to normal levels and reduced the number of tumour cells in the circulation and lymph nodes. Extended inhibition of AKT activity and rRNA synthesis with MK-2206 treatment of mice bearing Eμ-Myc B-cell lymphoma caused a significant delay in disease progression associated with increased tumor cell apoptosis.
Results

AKT signalling is required for rRNA gene transcription in vivo.
To establish the ability of MK-2206 to inhibit AKT activity and rDNA gene (Fig. 1A) . In contrast, total AKT abundance was not altered (Fig. 1A) . Furthermore, AKT inhibition was associated with suppression of 47S rDNA gene transcription, evident at 6 hours and statistically significant by 24 hours (45% decrease; (Fig. 2B) . MK-2206 treatment also prevented the typical expansion of the white blood cell population (Fig. 2C ) and the increase in lymph node size observed in the control mice at 24 and 48 hours post-treatment (Fig. 2D ).
MK-2206 treatment induces apoptosis of Eμ-Myc B-cell lymphoma cells in vivo.
We have previously demonstrated that inhibition of AKT activity leads to apoptosis of Eμ-Myc B-cell lymphoma cells in vitro [11] . To determine whether (Fig. 3A) and, as was observed following single dose treatment (Fig. 2) , this was associated with a significant reduction in both spleen weight (Fig. 3B ) and the population of circulating tumour cells (Fig. 3C ) compared to the control group. While MK-2206 treatment prolonged survival, the mice eventually succumbed to nodal and extra-nodal disease (Fig. 3D) . The extended survival of these mice compared to the control group is consistent with our observation in the single dose experiment ( (Fig. 3E ) and the spleens (Fig. S2B ) of mice repeatedly dosed with MK-2206, compared to control mice. Furthermore, MK-2206 treatment also induced an increase in the apoptotic, sub G1 cell population in the axillary lymph nodes (Fig. S2C) as determined by FACS analysis. This data is consistent with the induction of apoptosis as the major therapeutic mechanism through which pharmacological AKT inhibition delays lymphoma progression and prolongs survival in this B-cell lymphoma model.
Discussion
Dysregulation of ribosome biogenesis is no longer a passive readout for malignant transformation but is now a realistic therapeutic target [22, 32, 33] .
Our previous in vitro analyses characterised a critical role for AKT in the control of rDNA transcription at multiple levels including Pol I transcription elongation and/or processing of the rRNA, together with its control of mTORC1-dependent Pol I transcription initiation [11] .
Consequently, inhibiting AKT activity reduces rRNA synthesis more rapidly and potently than the mTORC1 specific inhibitor rapamycin alone [11] . Importantly for the current study, this was most notable in MYC driven B-cell lymphoma cells in vitro where reduced AKT activity resulted in potent inhibition of rRNA synthesis and cell death, while mTORC1 inhibition had little effect on either [11] . Here we show that this reliance of rRNA synthesis and cell survival on and it will be important to test this hypothesis in future in vivo studies.
In conclusion, our findings raise the exciting possibility that malignant diseases driven by dysregulation of the key controllers of cell growth including the MYC, PIK3CA and RAS oncoproteins, may be vulnerable to therapeutic strategies that target AKT signalling.
Experimental Procedures
All animal experiments were performed according to protocols approved by the institutional animal experimentation ethics committee.
MK-2206 preparation
MK-2206 was a gift from MERCK. MK-2206 was dissolved using sonication (50 Hz) in 30% (w/v) captisol (CyDEX) prepared in sterile water.
Preparation and transplantation of Eμ-Myc B-cell lymphoma into C57Bl/6 recipient mice
Eμ-Myc B-cell lymphoma cells (clone 4242) derived from an Eμ-Myc lymphoma and transduced with a MSCV GFP construct were generated as described previously [22] . Cells were thawed, washed and resuspended in phosphate-buffed saline (PBS) prior to intravenous injection into recipient C57Bl/6 mice (~2x10 5 cells/mouse). Disease was monitored by determining white blood cell counts (WBCC) from peripheral whole blood collected into 10
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Acute dose and repeated-dosing therapy
Mice were randomized into two groups, vehicle control or MK-2206 treated.
For the acute dose therapy 15 mice per group were treated with 30% captisol 
Histology
Spleens and inguinal lymph nodes were fixed in 10% neutral buffered formalin, embedded in paraffin wax, serially sectioned and processed for
Haematoxylin and Eosin (H&E) staining or TUNEL analysis (Millipore Apoptag
Peroxidase In situ Apoptosis Kit S7100) as described previously [22] .
Sections were analysed using the Olympic BX-51 at 40X magnification and quantitation of TUNEL staining performed with MetaMorph Microscopy
Automation & Image Analysis Software (Molecular Devices).
Single cell suspension from axillary lymph nodes
Single cell suspensions were generated from the axillary lymph nodes by grinding the tissue, filtering the cells through a 0.7µm filter and washing with 2% fetal bovine serum in PBS. Cell number was determined using the Z2
Coulter Counter (Beckman Coulter) and a proportion of cells used for FACS analysis of GFP/B220 expression or propidium iodide (PI) staining, also for extraction of protein or RNA.
FACS analysis for GFP/B22O expression
White blood cells isolated using red blood cell lysis buffer (144 mM NH4Cl, 17
mM Tris-HCl, pH7.65) and 1x10 6 axillary lymph node cells were analysed for
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Western analysis
Protein was extracted from axillary lymph node cells using SDS-lysis buffer (0.5 mM EDTA, 20 mM HEPES, 2% (w/v) SDS, pH 7.9), boiling at 95°C, shearing with a 26G needle and then centrifuged at 13000rpm for 10min.
Protein concentration was determined using the DC Protein Assay (BioRAD Samples were analysed on FACS Canto II (BD Pharmigen) and proportion of cells in the SubG1 region determined using FCSExpress software.
Statistical tests
The survival curve data was analysed using Mantel-Cox and Gehan-BreslowWilcoxin tests using GraphPad Prism Software. All the remaining data was assessed using a student t-test (two-tailed) using GraphPad Prism Software. 
